Global Erythroid Maturation Agent Market, By Type (Reblozyl, Others), Strength (25mg, 75mg, Others), Application (Anemia due to Beta-thalassemia, Anemia with Myelodysplastic syndrome (MDS)), Dosage (Injection, Powder, Others), Route of Administration (Subcutaneous, Other), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Erythroid Maturation Agent Market
Global erythroid maturation agent market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6.70% in the above mentioned forecast period.
Erythroid maturation agents are used for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions. It is also indicated for the treatment of anemia failing an erythropoiesis stimulating agent. These agents work by regulating red blood cell maturation. Reblozyl is the first and only erythroid maturation agent. It is also known as luspatercept.
Rise in the prevalence of anemia, growing healthcare expenditure, supportive strategies, growing government funding and growing use of the product for different conditions are the factors that will expand the erythroid maturation agent market.
Rise in the research and development activities and surge in the number of clinical trials will provide beneficial opportunities for the erythroid maturation agent market in the forecast period of 2021-2028.
However, high cost of medication and side effects of reblozyl such as hypertension, allergic reactions, headache, fatigue, nausea, diarrhea, abdominal pain, blood clots and upper respiratory reactions are the factors that will hinder the market growth and will further challenge the global erythroid maturation agent market in the forecast period mentioned above.
This erythroid maturation agent market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global erythroid maturation agent market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Erythroid Maturation Agent Market Scope and Market Size
The erythroid maturation agent market is segmented on the basis of type, strength, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the erythroid maturation agent market is segmented into reblozyl and others.
- On the basis of strength, the erythroid maturation agent market is segmented into 25mg, 75mg and others.
- On the basis of application, the erythroid maturation agent market is segmented into anemia due to beta-thalassemia, anemia with myelodysplastic syndrome (MDS).
- On the basis of dosage, the erythroid maturation agent market is segmented into injection, powder and others.
- On the basis of route of administration, the erythroid maturation agent market is segmented into subcutaneous and others.
- On the basis of end-users, the erythroid maturation agent market is segmented into clinic, hospital and others.
The erythroid maturation agent market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Erythroid Maturation Agent Market Country Level Analysis
Erythroid maturation agent market is analyzed and market size information is provided by the country, type, strength, application, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the erythroid maturation agent market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the erythroid maturation agent market due to the presence of major key players, well-developed healthcare sector and high disposable income in this region. Asia-Pacific is expected to grow during the forecast period 2021 to 2028 due to the increasing research and development activities, emerging markets, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Erythroid maturation agent market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Erythroid Maturation Agent Market Share Analysis
Erythroid maturation agent market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to erythroid maturation agent market.
The major players covered in the erythroid maturation agent market report are Acceleron Pharma Inc., and Bristol-Myers Squibb Company, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-